<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591474</url>
  </required_header>
  <id_info>
    <org_study_id>IRB3848</org_study_id>
    <nct_id>NCT00591474</nct_id>
  </id_info>
  <brief_title>The Influence of Probiotics on Vancomycin-Resistant Enterococcus</brief_title>
  <official_title>The Influence of Probiotics on Vancomycin-Resistant Enterococcus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drinking probiotics in a the form of a yogurt drink will restore normal gastrointestinal (GI)
      bacteria in patients whose colon are colonized with vancomycin-resistant enterococcus (VRE).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Anticipated">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whether a positive VRE colonized patient becomes VRE negative after drinking yogurt with probiotics</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to VRE clearance</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustainable effects of probiotics on VRE colonization</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any positive or negative effects on patients' hospital stay.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>GI Colonization of Vancomycin-Resistant Enterococcus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VRE positive patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>VRE positive patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotics</intervention_name>
    <description>100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>yogurt</intervention_name>
    <description>100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  VRE positive patients with GI colonization

        Exclusion Criteria:

          -  Age less than 18 years

          -  Patients who have had a bone marrow transplant

          -  Extreme short bowel patients (less than 100 cm small bowel remaining)

          -  Patients with active VRE infection but no GI colonization

          -  Patients unable to eat and have no feeding access

          -  Patients who do not have a power of attorney to give consent if they are unable to
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Martindale, MD, PH.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsinchen J Lin, MD</last_name>
    <phone>503-679-3944</phone>
    <email>linh@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Martindale, MD, Ph.D</last_name>
    <phone>503-494-9145</phone>
    <email>marindr@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OHSU hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hsinchen J Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Martindale, MD, PH.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc. 2006 Apr;81(4):529-36. Review.</citation>
    <PMID>16610573</PMID>
  </reference>
  <reference>
    <citation>National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004 Dec;32(8):470-85.</citation>
    <PMID>15573054</PMID>
  </reference>
  <reference>
    <citation>Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2002 Jun;46(6):1619-28. Review.</citation>
    <PMID>12019066</PMID>
  </reference>
  <reference>
    <citation>Joels CS, Matthews BD, Sigmon LB, Hasan R, Lohr CE, Kercher KW, Norton J, Sing RF, Heniford BT. Clinical characteristics and outcomes of surgical patients with vancomycin-resistant enterococcal infections. Am Surg. 2003 Jun;69(6):514-9.</citation>
    <PMID>12852510</PMID>
  </reference>
  <reference>
    <citation>Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, Perl TM, Hammond JM, Hendrix CW. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med. 2002 Jun;28(6):692-7. Epub 2002 Apr 12.</citation>
    <PMID>12107672</PMID>
  </reference>
  <reference>
    <citation>Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, Young JW, Kiehn TE, Zuccotti G. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007 May;13(5):615-21. Epub 2007 Mar 23.</citation>
    <PMID>17448922</PMID>
  </reference>
  <reference>
    <citation>Matar MJ, Tarrand J, Raad I, Rolston KV. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control. 2006 Oct;34(8):534-6.</citation>
    <PMID>17015161</PMID>
  </reference>
  <reference>
    <citation>Humphreys H, Dolan V, Sexton T, Conlon P, Rajan L, Creamer E, Walshe J, Donohoe J, Smyth EG. Implications of colonization of vancomycin-resistant enterococci (VRE) in renal dialysis patients. Learning to live with it? J Hosp Infect. 2004 Sep;58(1):28-33.</citation>
    <PMID>15350710</PMID>
  </reference>
  <reference>
    <citation>Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis. 2002 Nov 15;35(10):1139-46. Epub 2002 Oct 17.</citation>
    <PMID>12410472</PMID>
  </reference>
  <reference>
    <citation>Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother. 2003 Jun;51 Suppl 3:iii13-21. Review.</citation>
    <PMID>12801938</PMID>
  </reference>
  <reference>
    <citation>Kreman T, Hu J, Pottinger J, Herwaldt LA. Survey of long-term-care facilities in Iowa for policies and practices regarding residents with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci. Infect Control Hosp Epidemiol. 2005 Oct;26(10):811-5.</citation>
    <PMID>16276955</PMID>
  </reference>
  <reference>
    <citation>Bryce EA, Tiffin SM, Isaac-Renton JL, Wright CJ. Evidence of delays in transferring patients with methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus to long-term-care facilities. Infect Control Hosp Epidemiol. 2000 Apr;21(4):270-1.</citation>
    <PMID>10782590</PMID>
  </reference>
  <reference>
    <citation>Baden LR, Thiemke W, Skolnik A, Chambers R, Strymish J, Gold HS, Moellering RC Jr, Eliopoulos GM. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of &quot;clearance&quot;. Clin Infect Dis. 2001 Nov 15;33(10):1654-60. Epub 2001 Oct 10.</citation>
    <PMID>11595985</PMID>
  </reference>
  <reference>
    <citation>Dunne C. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm Bowel Dis. 2001 May;7(2):136-45. Review.</citation>
    <PMID>11383587</PMID>
  </reference>
  <reference>
    <citation>Vanderhoof JA, Young RJ. Current and potential uses of probiotics. Ann Allergy Asthma Immunol. 2004 Nov;93(5 Suppl 3):S33-7. Review.</citation>
    <PMID>15562872</PMID>
  </reference>
  <reference>
    <citation>McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006 Apr;101(4):812-22.</citation>
    <PMID>16635227</PMID>
  </reference>
  <reference>
    <citation>Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007 Jul 14;335(7610):80. Epub 2007 Jun 29.</citation>
    <PMID>17604300</PMID>
  </reference>
  <reference>
    <citation>Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust. 2007 May 7;186(9):454-7.</citation>
    <PMID>17484706</PMID>
  </reference>
  <reference>
    <citation>Hendrix CW, Hammond JM, Swoboda SM, Merz WG, Harrington SM, Perl TM, Dick JD, Borschel DM, Halczenko PW, Pelz RK, Rocco LE, Conway JE, Brower RG, Lipsett PA. Surveillance strategies and impact of vancomycin-resistant enterococcal colonization and infection in critically ill patients. Ann Surg. 2001 Feb;233(2):259-65.</citation>
    <PMID>11176133</PMID>
  </reference>
  <reference>
    <citation>Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002 Oct 28;162(19):2223-8.</citation>
    <PMID>12390066</PMID>
  </reference>
  <reference>
    <citation>Patel R, Allen SL, Manahan JM, Wright AJ, Krom RA, Wiesner RH, Persing DH, Cockerill FR, Thompson RL. Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients. Liver Transpl. 2001 Jan;7(1):27-31.</citation>
    <PMID>11150418</PMID>
  </reference>
  <reference>
    <citation>Montecalvo MA, de Lencastre H, Carraher M, Gedris C, Chung M, VanHorn K, Wormser GP. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol. 1995 Dec;16(12):680-5.</citation>
    <PMID>8683085</PMID>
  </reference>
  <reference>
    <citation>Roghmann MC, Qaiyumi S, Schwalbe R, Morris JG Jr. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol. 1997 Oct;18(10):679-80.</citation>
    <PMID>9350457</PMID>
  </reference>
  <reference>
    <citation>Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M, Valtonen V. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003 Mar 15;36(6):775-80. Epub 2003 Mar 5. Review.</citation>
    <PMID>12627362</PMID>
  </reference>
  <reference>
    <citation>Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol. 2000 Jan;95(1 Suppl):S2-4.</citation>
    <PMID>10634218</PMID>
  </reference>
  <reference>
    <citation>Vanderhoof JA. Probiotics: future directions. Am J Clin Nutr. 2001 Jun;73(6):1152S-1155S. Review.</citation>
    <PMID>11393194</PMID>
  </reference>
  <reference>
    <citation>Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr. 1999 Nov;135(5):564-8.</citation>
    <PMID>10547243</PMID>
  </reference>
  <reference>
    <citation>Alvarez-Olmos MI, Oberhelman RA. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin Infect Dis. 2001 Jun 1;32(11):1567-76. Epub 2001 May 4. Review.</citation>
    <PMID>11340528</PMID>
  </reference>
  <reference>
    <citation>Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol. 2005 Jan;21(1):44-50. Review.</citation>
    <PMID>15687884</PMID>
  </reference>
  <reference>
    <citation>Saxelin M, Chuang NH, Chassy B, Rautelin H, Mäkelä PH, Salminen S, Gorbach SL. Lactobacilli and bacteremia in southern Finland, 1989-1992. Clin Infect Dis. 1996 Mar;22(3):564-6.</citation>
    <PMID>8852980</PMID>
  </reference>
  <reference>
    <citation>Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, Bengmark S, Neuhaus P. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. Am J Transplant. 2005 Jan;5(1):125-30.</citation>
    <PMID>15636620</PMID>
  </reference>
  <reference>
    <citation>Rayes N, Seehofer D, Hansen S, Boucsein K, Müller AR, Serke S, Bengmark S, Neuhaus P. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation. 2002 Jul 15;74(1):123-7.</citation>
    <PMID>12134110</PMID>
  </reference>
  <reference>
    <citation>Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, Kouri M, Elomaa I, Joensuu H. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007 Oct 22;97(8):1028-34. Epub 2007 Sep 25.</citation>
    <PMID>17895895</PMID>
  </reference>
  <reference>
    <citation>Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, De Renzis C, Famularo G. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol. 2002 Aug;97(8):2150-2.</citation>
    <PMID>12190202</PMID>
  </reference>
  <reference>
    <citation>Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, Koskela M. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis. 1999 May;28(5):1159-60.</citation>
    <PMID>10452653</PMID>
  </reference>
  <reference>
    <citation>Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect. 1999 May;5(5):290-292.</citation>
    <PMID>11856270</PMID>
  </reference>
  <reference>
    <citation>Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005 Jan;115(1):178-81.</citation>
    <PMID>15629999</PMID>
  </reference>
  <reference>
    <citation>Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004 Apr;38(4):457-8.</citation>
    <PMID>15085028</PMID>
  </reference>
  <reference>
    <citation>De Groote MA, Frank DN, Dowell E, Glode MP, Pace NR. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J. 2005 Mar;24(3):278-80.</citation>
    <PMID>15750472</PMID>
  </reference>
  <reference>
    <citation>Klare I, Konstabel C, Werner G, Huys G, Vankerckhoven V, Kahlmeter G, Hildebrandt B, Müller-Bertling S, Witte W, Goossens H. Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J Antimicrob Chemother. 2007 May;59(5):900-12. Epub 2007 Mar 16.</citation>
    <PMID>17369278</PMID>
  </reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>January 10, 2008</last_update_submitted>
  <last_update_submitted_qc>January 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert Martindale M.D.</name_title>
    <organization>OHSU</organization>
  </responsible_party>
  <keyword>VRE</keyword>
  <keyword>Probiotics</keyword>
  <keyword>colonization</keyword>
  <keyword>gut health</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

